Newsroom

Temple University Hospital (TUH) will conduct a multi-centered, randomized, Phase 3 research study to learn if the experimental drug recombinant Factor VIIa (rFVIIa), a protein that our body makes, can be used to decrease bleeding in the brain of patients who suffer sudden bleeding in the brain, also called intracerebral hemorrhage (ICH).

Bold initiative designed to transform the clinical research landscape by training, developing and mentoring new clinical investigators dedicated to increasing clinical trial diversity.

Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ, Adjunct Associate Professor of Family and Community Medicine and Adjunct Associate Professor of Urban Bioethics and Population Health at the Lewis Katz School of Medicine at Temple University, offered insight for a USA Today article on findings by the U.S. Centers for Disease Control and Prevention (CDC) which showed that Black, Hispanic and Native American people continue to be more likely to be hospitalized with the flu and less likely to be vaccinated against it.